Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope

DOI: 10.1080/2162402X.2016.1216290

Keywords: CpG-B, HLA-DR7, long synthetic peptide, malignant melanoma, NY-ESO-1

Full-Text   Cite this paper   Add to My Lib

Abstract:

Full-Text